Unceremoniously dumped by its partner Johnson & Johnson in early 1998, Amylin struggled to carry on developing amylin--a hormone once hyped as "the missing link" in diabetes treatment. After twice failing to produce clinical evidence that the peptide benefitted diabetic patients, Amylin laid off 80% of its employees, and fell off Nasdaq's big board. Most investors dismissed the company, and their stake in it, as a lost cause. Amylin got a second chance in March 1999, via a private Series A financing. It's too soon to say whether the leap of faith by Amylin's new investors will be rewarded. The firm's aspirations for its lead drug are more modest now than in earlier days. It has no partner, and knows uncertainty still exists in the FDA process. Meanwhile, competitors' oral drugs are helping many Type 2 diabetics.
by Deborah Erickson Unceremoniously dumped by its partner
Johnson & Johnson in early 1998, Amylin struggled to carry on
developing amylin—a hormone once hyped as "the missing
link" in diabetes treatment.
Amylin Pharmaceuticals Inc. was on top of the world in June 1995. Or at least, the company's founder and...
Candid conversations with C-suite leaders.
Keep up with strategy, innovation and evolving trends across life science industries.
The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.
Digital clinical trials, a trend sparked by the COVID-19 pandemic that has held the biopharma industry’s interest, are changing the way patients interact with research and improving access, says Medable’s CEO.
INFOGRAPHIC: Deal volume for both M&A and alliances fell in 2023, but average valuations rose appreciably. Antibody-drug conjugates for cancer drove high-value acquisitions and partnerships.
Introducing the all-new Citeline News and Insights app, providing seamless access to all your favorite award-winning publications. Explore the latest articles from Pink Sheet, Scrip, In Vivo, Medtech Insight, Generics Bulletin and HBW Insight, all in one stylish, intuitive and user-friendly platform.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.